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With isolated limb perfusions (ILP) high drug concentrations can
be achieved in the vasculature of a limb with no or negligible
leakage into the systemic circulation. With the addition of high
dose tumour necrosis factor alpha (TNF-a) to melphalan high
response rates were demonstrated in patients with melanoma and
irresectable soft tissue sarcomas (Liénard et al, 1992; Eggermont
et al, 1996a, 1996b). Similarly, in rat sarcoma models synergy has
been demonstrated between melphalan and TNF-a (Manusama
et al, 1996; de Wilt et al, 1999).
The exact mechanisms for synergistic anti-tumour effects
between melphalan and TNF-a, however, are not clear. Several
possible mechanisms have been suggested such as selective
destruction of tumour vasculature, which is accompanied by
thrombus formation and haemorrhagic necrosis of the tumour
(Shimomura et al, 1988; Renard et al, 1995). This process is
accompanied by an inflammatory response that seems to be
leucocyte-dependent (Yi and Ulich, 1992; Renard et al, 1994;
Manusama et al, 1998). Moreover, TNF-a increases the perme-
ability of tumour vasculature (Folli et al, 1993; Umeno et al, 1994)
and has been reported to lower interstitial pressure in the tumour
(Kristensen et al, 1996), which could both increase leakage of
melphalan in tumour tissue and explain the observed synergy.
To demonstrate this hypothesis we analysed melphalan concen-
trations in tumour and limb tissue after melphalan isolated limb
perfusions with and without the addition of TNF-a.
MATERIALS AND METHODS
Chemicals
Melphalan (Alkeran, Wellcome, Beckenham, UK) was diluted in
0.9% sodium chloride and stored at –20°C. Recombinant human
TNF-a was provided by Boehringer (Ingelheim, Germany), with
specific activity of 5.8 ´ 107 U mg–1 and endotoxin levels < 1.25
endotoxin units (EU) per mg protein and stored at –80°C. During
perfusion 40 mg melphalan with or without 50 mg TNF-a was
used.
Animal tumour model and perfusion setting
Male inbred BN rats, weighing 250–300 g, obtained from Harlan-
CPB (Austerlitz, The Netherlands) were used. The perfusion tech-
nique was performed as described previously (Manusama et al,
1996). Briefly, small tumour fragments of the non-immunogenic
BN-175 soft-tissue sarcoma were implanted in the right hind limb.
ILP was performed at a tumour diameter of 13 mm ± 3 mm at least
7 days after implantation. Animals received 50 IU of heparin and
the hind limb was kept at a constant temperature of 38–39°C. The
femoral artery and vein were cannulated and collaterals were
occluded by a groin tourniquet. An oxygenation reservoir was
included into the circuit, and melphalan and TNF-a were added as
boluses herein. A roller pump recirculated the perfusate at a flow
rate of 2.4 ml min–1 for 30 min. A washout with 5 ml oxygenated
Haemaccel was performed at the end of the perfusion. The
committee on Animal Research of the Erasmus University
Rotterdam, The Netherlands, approved the experimental protocol.
Tumour growth after perfusion was daily recorded by calliper
measurement. Tumour volume was calculated as 0.4(A2B), where
A is the minimal tumour diameter and B the diameter perpendic-
ular to A. Tumour volumes were compared 5 days after perfusion.
Assessment of melphalan concentrations in tissue
Immediately after ILP the perfused tumour and hind limb tissues
were excised, homogenized in 2 ml acetonitrile (PRO 200 homo-
genizer, Pro Scientific, CT, USA), centrifuged at 2500 g and stored
at –80°C. Melphalan was measured by gas chromatography-mass
spectrometry (GC-MS), as described previously (De Boeck et al,
1997). P-[Bis(2-chloroethyl)amino]-phenylacetic acid methyl
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ester was used as an internal standard. Samples were extracted
over trifunctional C18 silica columns. After elution with methanol
and evaporation, the compounds were derivatized with trifluoro-
acetic anhydride and diazomethane in ether. The stable derivatives
were separated on a methyl phenyl siloxane GC capillary column
and measured selectively by single ion monitoring GC-MS in the
positive EI mode.
Statistical analysis
Mann–Whitney U-test was used to compare tumour volumes in
different animal groups and to compare melphalan concentrations
in different groups.
RESULTS
Tumour response after ILP
Mean tumour volumes were compared to demonstrate the efficacy
of ILP with TNF-a and melphalan. Four groups of rats were
perfused with sham (n = 10), TNF-a alone (n = 10) melphalan
alone (n = 10) and the combination of TNF-a and melphalan
(n = 10). A synergistic anti-tumour response was observed with
the combination of melphalan and TNF-a as demonstrated before
(Manusama et al, 1996; de Wilt et al, 1999) (Figure 1). A signifi-
cant decrease in mean tumour volume after perfusions with the
combination of melphalan and TNF-a was observed (P < 0.001),
whereas in all other perfusions tumour volume increased.
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Figure 1 Mean tumour volumes (± s.e.m.) of BN-175 sarcoma before (n n) and 5 days after (n) ILP
Figure 2 Melphalan concentration (± s.e.m.) in skin/muscle tissue (n n) and tumour tissue (n) immediately excised after ILP with melphalan with or
without TNF-a1002 JHW de Wilt et al
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Tissue concentrations of melphalan
Figure 2 demonstrates a sixfold increased melphalan concentration
was found in tumour tissue after perfusion with the combination of
TNF-a and melphalan (n = 6) in comparison with perfusions with
melphalan alone (n = 6) (P = 0.01). TNF-a had no effect on skin
and muscle tissue since melphalan concentrations after ILP were
comparable with or without the addition of TNF-a.
DISCUSSION
In the present study we demonstrate an increased accumulation
of melphalan in tumour tissue after ILP with the combination
of melphalan and TNF-a as compared to melphalan alone. The
increased melphalan accumulation could not be demonstrated in
skin and muscle tissue, suggesting that TNF-a has no effect on
normal tissue. The increased melphalan concentration in tumour
tissue correlates very well with the observed tumour response.
The observed responses in this rat soft-tissue sarcoma model are
comparable to patients, where TNF-a (Posner et al, 1994) or
melphalan alone is not or only marginally active (Klaase et al,
1989). The combination of TNF-a and melphalan, however,
results in high response rates (Liénard et al, 1992; Eggermont et al,
1996a, 1996b). Addition of TNF-a seems crucial in the observed
synergy with melphalan and several mechanisms could be respon-
sible for this. A direct effect of TNF-a on the anti-tumour activity
of melphalan on BN-175 tumour cells was previously ruled out in
vitro (Manusama et al, 1996).
Fajardo et al (1992) previously demonstrated that low-dose
TNF-a has a proliferative effect on angiogenesis, whereas higher
doses can cause destruction of newly formed blood vessels. It has
been demonstrated that this destruction of blood vessels is the
result of apoptosis and detachment of angiogenic endothelial cells
(Ruegg et al, 1998) which may lead to thrombocyte aggregation,
erythrostasis and haemorrhagic necrosis (Shimomura et al, 1988;
Renard et al, 1994, 1995; Nooijen et al, 1996).
Whereas previous studies focus on tumour regression resulting
from TNF-a-mediated destruction of the vasculature we show that
augmented melphalan concentrations in tumour tissue after ILP
with TNF-a correlates very well with tumour response and
provides an elegant and straightforward explanation for the
observed responses. Similarly, drug accumulation in tumour tissue
has been shown after systemic pretreatment with TNF-a in mice
treated with liposomal doxorubicin (Suzuki et al, 1990; Maruo et
al, 1992). An explanation for this phenomenon can be the
increased vascular permeability or decreased interstitial pressure
that was demonstrated after administration of TNF-a (Folli et al,
1993; Umeno et al, 1994; Kristensen et al, 1996). Alexander et al
(1998) demonstrated an increased capillary leakage during isolated
hepatic perfusions (IHP) and an increased uptake of I-131 albumin
in tumour tissue compared to liver tissue. However, addition of
TNF-a did not affect melphalan concentrations in tumour tissue
after IHP. Several reasons for this discrepancy are possible such as
concentration of TNF-a used, sampling method and duration of
perfusion. Another reason can be the difference in tumour vascula-
ture, since colorectal metastases are usually hypovascular and
largely necrotic, whereas soft-tissue sarcoma are usually hyper-
vascular.
In conclusion, we hypothesise that increased tumour concentra-
tion of melphalan could very well be the main mechanism by
which TNF-a enhances the anti tumour response. This finding is
not only important for further TNF-a-based limb perfusions using
melphalan or other cytostatic agents, but also for other perfusions
settings such as isolated liver (Borel Rinkes et al, 1997; Alexander
et al, 1998), lung (Pogbreniak et al, 1994) or kidney perfusions
(van der Veen et al, 1999).
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